多西他赛（泰索帝）：转移性尿路上皮癌的一种活性药物；非化疗预处理患者的II期研究结果
Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
作者信息
de Wit R, Kruit W H, Stoter G, de Boer M, Kerger J, Verweij J
机构信息
Rotterdam Cancer Institute and University Hospital, The Netherlands.
出版信息
Br J Cancer. 1998 Nov;78(10):1342-5. doi: 10.1038/bjc.1998.681.
The semisynthetic taxoid docetaxel was investigated in a phase II study in non-chemotherapy pretreated patients with metastatic urothelial cell cancer. Thirty patients (median age 61, range 45-72) were treated with docetaxel 100 mg m(-2) administered as a 1-h infusion every 3 weeks. Of 29 evaluable patients, four achieved a complete response and five a partial response, for an overall response rate of 31%. The median duration of response was 6 months (range 4-51+). A total of 104 cycles were administered. The median number of cycles given was three (range 1-9). Toxic effects of docetaxel mainly consisted of neutropenia, which, however, rarely caused infectious complications (5%). Fluid retention or neuropathy necessitated treatment cessation in two patients. We conclude that docetaxel is an effective agent in urothelial cell cancer, and should be further tested in combination chemotherapy.
在一项针对未经化疗预处理的转移性尿路上皮细胞癌患者的II期研究中，对半合成紫杉烷类多西他赛进行了调查。30例患者（中位年龄61岁，范围45 - 72岁）接受多西他赛100 mg/m²治疗，每3周静脉输注1小时。在29例可评估患者中，4例达到完全缓解，5例达到部分缓解，总缓解率为31%。中位缓解持续时间为6个月（范围4 - 51+）。共进行了104个周期的治疗。给予的周期中位数为3个（范围1 - 9）。多西他赛的毒性作用主要包括中性粒细胞减少症，然而，很少引起感染并发症（5%）。两名患者因液体潴留或神经病变而需要停止治疗。我们得出结论，多西他赛在尿路上皮细胞癌中是一种有效的药物，应在联合化疗中进一步进行测试。
Zotero 插件